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ABSTRACT' 
Assessment of nasal symptoms was performed using TOTAL NASAL SYMPTOM SCORE 
at the beginning of the study, 10 and 30 days later.  
More significant reduction in the severity of nasal congestion was found among patients who 
received both Levocetirisinum and Montelucastum. Also the use of montelukastum as an 
additional drug in symptomatic therapy of chronic allergic rhinitis reduces the need for 
intranasal topical glucocorticosteroids compared to patients who received only  
antihistamines per os.  
Allergic rhinitis is the most common atopic disorder affecting millions  
people annually all over the world.  The choice of the  optimal treatment  
of allergic rhinitis depends on different factors and conditions. The best option is avoidance of implicated allergens, but unfortunately it is not 
always possible and most of patients using symptomatic drugs. We compared 2 groups of patients with chronic allergic rhinitis. The first one was 
taking just Levocetirisinum 5 mg daily. And patients of the second group except Levocetirisinum 5 mg where taking Montelucastum 10 mg.  
  
By the 10th day of treatment, there was a marked decrease in the severity  
 
of nasal symptoms in both groups.  
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Introduction. Allergic rhinitis (AR) is the most common atopic disease 
characterized by such symptoms as rhinorrhea, sneezing, and nasal congestion 
[4]. These symptoms reduce the quality of patient`s life, affect on daily 
activities, and also reduce the quality of sleep and productivity. At the same 
time, economic losses because of the AR, for example, in the US annually 
accounts for 2.4-4.6 billion dollars [3]. According to the European Community 
Respiratory Health Survey, which included 140,000 volunteers from 22 
countries, the prevalence of AR is about 21 % (Janson C. et al., 2001). And the 
proportion of patients with undiagnosed AR ranges from 25-60% (Bauchau V., 
Durham S. R., 2004). According to these authors, specific IgE is detected in 83 
% of patients with diagnosed AR. The most common allergens are pollen 
grasses (52 %), house dust (49 %), pollen of trees (33 %), pollen of weeds (27 
%), skin and animal hair (26 %), spores of mold fungi (10 %) [5].  
Copyright: © 2018  
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice.  
This is an  
No use, distribution or reproduction is permitted which does not comply with these terms.  
  
It should be noted that inadequate control of AR, in addition to sleep disorders, increased day fatigue, learning disabilities, and 
a decrease in overall cognitive functioning, can lead to the development of pathological conditions such as acute and chronic 
sinusitis, otitis media, sleep apnea and exacerbation of existing diseases [5].  
One of the methods of treating allergic diseases, along with the elimination of allergen and immune therapy is the use of 
pharmacotherapy to control the symptoms of the disease. Leukotriene receptor antagonists could be attributed to this group [6, 
7]. The mechanism of action of these drugs is  
based on blocking the action of leukotrienes, one of the proinflammatory mediators, at the receptor  
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level. In our days the ability of montelukastum to reduce bronchial obstruction 
is well known. But  
there is a question about the systemic anti-inflammatory effect of this drug and 
the possibility of its  
use in the complex therapy of alergic rhinitis [1, 2].  
to assess the effectiveness of montelukastum in the treatment of chronic  
Purpose of the study:  
allergic rhinitis  
Materials and methods. The study included patients with established diagnosis 
of chronic allergic rhinitis, the stage of exacerbation. The average age is 34.6 ± 
7.7 years. Male 17, female 33. The duration of the disease for the whole group 
was 7.2 ± 2.15 years. Patients were randomly divided into 2 groups. The first 
group (n = 20) - patients who received Levocetirisinum 5 mg (Levocetirizin- 
astrapharm, Asrapharm, Ukraine) in the morning as a therapy. The second group 
(n = 30) - the patients who received Montelucastum 10 mg for the night (Drug 
"Montular", Kusum Pharm, Ukraine) and Levocetirisinum 5 mg (Levocetirizin-
astrapharm, Asrapharm, Ukraine) in the morning as a therapy. The duration of 
the observation was 30 days. Assessment of nasal symptoms was performed 
using Total Nasal Symptom Score at the beginning of the study, 10 and 30 days 
later.  
For the processing of the initial statistical information, the programs Statistica 
and Excel were applied.  
Research results.  
Table 1. Dynamic of the total nasal symptom score  
Table& 1.& DYNAMIC( OF( THE( TOTAL( NASAL" SYMPTOM"
SCORE!
! First&group! Second'group!
At#the#biginning#
of#the#study!
3,9!±"0,52*! 3,93!±"0,51*!
In#10#days! 2,#14#±"0,44! 1,#98#±"0,5!
In#30#days! 1,29!±"0,32*! 1,19!±"0,49*!
 
(* p<0,01 the reliability of the differences for 30 days from the start of therapy in each group)  
When analyzing each indicator of the Total Nasal Symptom Score, a significant 
reduction in the severity of nasal congestion among patients of both groups was 
found, but a more pronounced decrease of this indicator was observed among 
patients who received combination therapy: an antihistamine receptor blocker 
and an antileukotriene drug. The nasal congestion index significantly decreased 
among patients of the first group by 78.3 %, the second - by 88.57 % (p <0.05) 
(Table 2).  
 
Table 2. Dynamics of individual indicators of the total nasal symptom score  
In the second group, at the end of the study, 60 % of patients stopped using 
intranasal topical glucocorticosteroids as adjuvant therapy. Whereas among 
patients who received only an antihistamine only 25 % of patients could refuse 
to use this group of drugs.  
Conclusions. Thus, the use of montelukastum as an additional drug in 
symptomatic therapy of chronic allergic rhinitis improves the quality of life of 
patients with allergic rhinitis, significantly reduces the severity of nasal 
congestion, and also reduces the need for intranasal topical glucocorticosteroids 
compared to patients who received only antihistamines per os.  
 
Table 2. DYNAMICS OF INDIVIDUAL INDICATORS OF THE TOTAL NASAL 
SYMPTOM SCORE 
! First&group! Second'group! p!
! At# the#
biginning% of%
the$study!
In#30#days! At# the#
biginning% of%
the$study!
In#30#days!
Nasal$
congestion!
4,8!±"0,67! 1,04!±0,33! 4,9!±"0,64! 0,56!±"0,22! p<0,05!
Runny$nose!! 3,94!±"0,69! 1,26!±"0,43! 3,74!±"0,51! 1,35±"0,45! p>0,05!
Nasal$itching! 3,6!±"0,51! 1,15!±"0,43! 3,56!±"0,5! 1,2$±"0,43! p>0,05!
Sneezing&! 3,36!±"0,49! 1,62!±"0,47! 3,75!±"0,44! 1,84%±"0,65! p>0,05!
Difficult'sleep! 4,02!±"0,54! 1,4!±"0,"39! 3,7!±"0,42! 0,98%±"0,39! p>0,05!
By the 10th day of treatment, there was a exprecced decrease in the severity  
 
of nasal symptoms in both groups. Both variants of therapy provided a further 
decrease in the total assessment of the severity of nasal symptoms according to 
Total Nasal Symptom Score by day 30 to  
 
1.41 ± 0.32 and 0.75 ± 0.49, respectively in each group (Table 1). http://ws-
conference.com/ No 6(34), Vol.5, June 2018 21  
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